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Barriers to using new needles encountered
by rural Appalachian people who inject
drugs: implications for needle exchange
Stephen M. Davis1,2* , Alfgeir L. Kristjansson3, Danielle Davidov2,3, Keith Zullig3, Adam Baus3 and Melanie Fisher4

Abstract
Background: Using a new needle for every injection can reduce the spread of infectious disease among people
who inject drugs (PWID). No previous study has examined new needle use barriers among PWIDs residing in the
rural Appalachian part of the United States, an area currently in the midst of a heroin epidemic.
Objective: Therefore, our primary aim was to explore self-reported barriers to using a new needle by PWID attending
a needle exchange program (NEP).
Methods: We conducted a cross-sectional survey of PWID attending two NEPs in rural West Virginia located in the
heart of Central Appalachia. A convenience sample of PWID (n = 100) completed the Barriers to Using New Needles
Questionnaire.
Results: The median number of barriers reported was 5 (range 0–19). Fear of arrest by police (72% of PWID “agreed” or
“strongly agreed”) and difficulty with purchasing needles from a pharmacy (64% “agreed” or “strongly agreed”) were
the most frequently cited barriers.
Conclusions/Importance: Congruent with previous findings from urban locations, in rural West Virginia, the ability of
PWID to use a new needle obtained from a needle exchange for every injection may be compromised by fear of
arrest. In addition, pharmacy sales of new needles to PWID may be blunted by an absence of explicit laws mandating
nonprescription sales. Future studies should explore interventions that align the public health goals of NEPs with the
occupational safety of law enforcement and health outreach goals of pharmacists.
Keywords: Needle exchange programs, Hepatitis C virus, People who inject drugs, Paraphernalia laws, Barriers to using
new needles, Policing behaviors

Introduction
The United States (US) is currently in the midst of a
hepatitis C virus (HCV) epidemic that has been catalyzed by injection drug use in rural areas. Cases of acute
HCV infection in the US increased 98% between 2010
and 2015 with consistent annual increases observed
during this time period [1]. Approximately 60 to 70% of
HCV cases in the US occur in people who inject drugs
(PWID) [2, 3]. The prevalence of HCV infection in PWID
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ranges between 40 and 90% and has been observed to be
as high as 98% [4]. A disproportionate number of new
HCV cases occur in young, white PWID residing in the
rural, Central Appalachian region of the US, which
includes the states of Kentucky, Tennessee, Virginia, and
West Virginia [1, 2, 5–7]. This region observed a 364%
increase in new HCV cases among young persons
(aged ≤ 30 years) between 2006 and 2012 [6]. Additionally,
in 2015, West Virginia had the second-highest rate of
acute HCV infections (3.4 per 100,000) in the US followed
by Kentucky (2.7 per 100,000) and Tennessee (2.6 per
100,000) [1]. This exponential increase in HCV cases has
been associated with prescription opioid misuse that
progresses to injection of heroin [8–11].
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Among PWID, the risk of HCV seroconversion increases
94% [pooled risk ratio = 1.94, 95% confidence interval (CI),
1.53, 2.46] when syringes are shared during injection [12].
In an effort to minimize the reuse of needles, needle
exchange programs (NEP) have been implemented as a
mechanism for exchanging used needles for new needles
[10, 13]. Although the ability to access new needles is one
important step in fighting the HCV epidemic, there are
potential barriers to using new needles obtained from
exchange programs that may reduce the efficacy of NEPs.
Previous studies have examined barriers to using a
new needle for every injection among PWID in large,
diverse urban settings. These studies have consistently
found direct associations between fear of law enforcement encounters (e.g., arrest, citation, syringe confiscation), syringe sharing [14–18], and injection equipment
sharing [16, 19]. Indirectly, fear of law enforcement
encounters has been associated with lack of access to
new needles from reduced exchange program participation [17, 20–22], and a reluctance to carry new needles
[19, 23, 24], which can increase risky injection behavior
[25, 26]. Peer group perceptions [27] and drug withdrawal
[14] have also been associated with risky injection behavior. No information currently exists describing the new
needle use barriers experienced by PWID in the rural,
central Appalachian region of the US that is in the midst
of historic heroin and HCV epidemics [28]. In comparison
to urban and suburban locations, rural areas have fewer
NEPs with less staffing and available budgets that may
impact access to new needles [29]. Additionally, conservative states such as West Virginia have histories of favoring
a criminal response versus a public health response to
drug use, which may increase potential fear of arrest by
PWID [30]. Therefore, the aim of this exploratory study
was to identify self-reported barriers to using a new needle
obtained from an exchange program among PWID
attending NEPs in the state of West Virginia, which is
located in the heart of Central Appalachia in the US.
Improved understanding of these barriers may have implications for the efficacy of needle exchange for the prevention of HCV in rural areas. Based on the previous
research [31], we hypothesized that fear of arrest and drug
withdrawal would be the most frequently reported barriers
to using a new needle.

Methods
Design

We conducted a cross-sectional survey of PWID attending the first two NEPs to open in West Virginia, the
Cabell-Huntington Health Department Syringe Exchange
[32] and the Mylan Puskar Health Right LIGHT (Living
in Good Health Together) Program [33]. The Cabell-Huntington Health Department Syringe Exchange is operated
by a county health department located in the southern
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part of West Virginia that has been described as the overdose capital of the US [34], while the LIGHT Program is
operated by a free healthcare clinic in another high PWID
prevalence area located close to the northern border with
Pennsylvania. Both programs exchange used needles for
new needles. PWIDs are encouraged to bring all needles
back, but the exchange is not dependent on the number
of needles returned. At the time of the study, the health
department limited the number of needles per PWID due
to budgetary constraints. The LIGHT Program did not
have a specific limit and distributed new needles on a
needs basis. We specifically selected these two NEPs because they were the only programs open at the time of
study design and thus had an established client base and
study operation flow. Furthermore, the primary author
had established relationships with each NEP director,
which facilitated survey implementation and logistics.
Measures

Previous studies examining barriers to new needle use
employed variable measurement methods that ranged
from qualitative interviews [14], quantitative surveys [19],
or mixed methods approaches [15, 35], with different
variable operationalizations. To facilitate approximate
comparisons to new needle use barriers experienced by
urban PWID, we chose to use the Barriers to Using New
Needles Survey (Cronbach’s alpha = .84) [31] that was
administered to a convenience sample of urban heroin
users in Denver, Colorado, in the western US. This questionnaire consists of 20 possible items regarding barriers
to using a new needle gleaned from clinical work and
qualitative interviews. Each participant indicates the
extent to which s/he agrees with each item (barrier)
according to a 5-point Likert scale ranging from “strongly
disagree” to “strongly agree.”
To test the comprehension and completeness of the survey [36, 37], two focus groups with 8 PWIDs (4 males, 4
females) drawn from attendees at both the Health Department NEP (n = 5) and the LIGHT Program (n = 3) were
conducted. Guiding questions were based on whether (1)
items were understandable, (2) response choices were
adequate, (3) items were written in a manner that elicited
only one response, and (4) items were complete. Item
modifications were made as needed to maximize their
applicability to the rural setting and avoid poorly defined
words or terms that were not universally understood [38].
To further enhance reliability and increase validity, the
directors of both NEPs also reviewed these items. All
respondents believed the items were complete (i.e., no
potential barriers were missed) and written in a manner
that only elicited one response. Participants also felt that
response choices (i.e., the 5-point Likert scale) were
adequate and that most items were understandable with
the exception of item 8 that discussed the potential barrier
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of using a new needle while injecting in a shooting
gallery. Several participants were unfamiliar with the term
“shooting gallery.” Therefore, we added a clarifying definition and a few terms (i.e., “dope den,” “joy popping”)
taken directly from the transcripts of the focus groups that
reflect the concept of a shooting gallery in our setting.
Otherwise, no other changes were made to the questionnaire (see Additional file 1 for specifics).
After item modifications, basic demographic questions
querying age, gender, race/ethnicity, education level,
employment status, housing status, HCV status, and
injection history (e.g., frequency of injecting, years of
injecting) were included in the final questionnaire (see
Additional file 1). To minimize potential bias stemming
from participant and item nonresponse, the final survey
was designed and pilot tested to take no more than 3–5
min to complete [36, 39]. Importantly, to minimize social
desirability bias given the sensitive nature of the questions,
the survey was anonymous [38].
Participants and procedure

Based on consultation with the NEP directors, a convenience sample of 100 attendees was planned. This
sample size was selected based on the following considerations: (1) NEP director’s assessment of maximum
number of accessible participants and (2) the unstable
and transient nature of the target population. To promote the number of responses, participants were personally invited by study staff to take the survey while
attending the exchange [39]. The only requirements for
participation were current exchange attendance and being at least 18 years of age. Those attendees agreeing to
participate were given a pen and completed the survey
on paper with study staff available to answer any questions regarding survey items. Participants were given a
$10 gift card upon completion of the questionnaire. The
West Virginia University Institutional Review Board approved the study and waived the requirement for written
informed consent given that the only document linking
participants to the sensitive and potentially stigmatizing
questionnaire would be the consent form.
Statistical analysis

All questionnaire data were entered into JMP® 13.0 Pro
[40]. The median was imputed in cases where respondents gave a range of values instead of a single number
(i.e., 5–10 injections = 7.5 injections; 47% of cases) and
in the 8% of cases with missing injection history. Frequencies and descriptive statistics were calculated for all
measured variables. The extent to which demographic
characteristics differed between respondents at each
NEP was assessed using chi-square (or Fisher’s exact test
when more than 20% of expected cell counts were < 5)
for nominal or ordinal variables, and the t test (or
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Wilcoxon test in the case of non-normally distributed outcomes) for continuous variables. Normality of outcomes
was assessed via the Shapiro-Wilk W test. Continuous
variables that significantly departed from normality were
recoded into an ordinal variable based on distribution
quartiles and a goal of creating category cell sizes that met
the chi-square test requirement of no more than 20% of
cells with expected counts < 5.
Barriers to using new needles

The 5-point Likert response indicating agreement with
each barrier was collapsed into a dichotomous “agree”
(responses of “agree,” “strongly agree”) and “disagree”
(responses of “strongly disagree,” “disagree,” “neutral”)
variable for analysis to allow comparisons with a previous cohort of Denver heroin injectors that completed
the Barriers to Using New Needles Questionnaire [31].
Contingency table analysis was used to explore bivariate
associations between nominal and ordinal demographic
and injection history factors and (1) the number of
barriers reported (< 4, 4–8, > 8) and (2) agreement (i.e.,
responses of “agree,” “strongly agree”) with the individual barriers to new needle use that were endorsed by
more than 50% of respondents. Analysis of variance
(ANOVA) was used to examine associations between
age and reported barriers. An alpha of .05 was selected
as the threshold for statistical significance.

Results
Participants

Overall, 100 PWIDs (Health Department, n = 74; LIGHT
Program, n = 26) were approached and agreed to take the
modified questionnaire. Respondents were generally young
(i.e., < 40 years; range = 18–63 years) and non-Hispanic
White with slightly more males than females completing
the questionnaire. Most respondents (78%) reported no
education beyond high school, and two thirds (66%)
were either unemployed or unable to work. A substantial portion of respondents (40%) reported that they
were currently homeless and one third were HCV positive. Respondents reported injecting between 1 and 18
times a day, 2 to 150 times a week, for 1 month to 35
years. There were no statistically significant differences
between NEP sites in any of the demographic variables
measured (see Table 1).
Drug of choice

Drug of choice information was available for 94 participants. Heroin was the most frequently cited drug of
choice by respondents (n = 67, 71.27%). Other drugs of
choice included methamphetamine (n = 16, 17.02%),
buprenorphine (n = 11, 11.70%), cocaine (n = 2, 2.13%),
fentanyl (n = 1, 1.06%), and amphetamines (n = 1, 1.06%).
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Table 1 Participant characteristics
Demographics

All (n = 100)

Health department (n = 74)

LIGHT Program (n = 26)

Age (avg.)

37.05

37.97

34.42

P*
.1307

%

n

%

n

%

Female

43

33

44.60

10

38.46

Male

57

41

55.40

16

61.54

< High school

21

19

25.68

2

7.69

High school graduate

57

39

52.70

18

69.23

> High school

22

16

21.62

6

23.08

White

96

71

95.95

25

96.15

Black/African American

4

3

4.05

1

3.85

Yes

1

1

1.35

0

0

No

98

72

97.30

26

100

Missing

1

1

1.35

0

0

22

15

20.27

7

26.92

Gender

.5869

Education

.1420

Race

1.000

Hispanic

1.000

Employment status
Employed
Unemployed

42

30

40.54

12

46.15

Unable to work

24

20

27.03

4

15.39

Other (e.g., student)

12

9

12.16

3

11.54

Yes

40

33

44.60

7

26.92

No

60

41

55.40

19

73.08

Yes

32

25

33.78

7

26.92

No

58

41

55.41

17

65.39

Do not know

10

8

10.81

2

7.69

5

5

.6539

Homeless

.1136

Hepatitis C positive

.6702

Injection history
Daily injections (median)

5

.6776

Weekly injections (median)

30

30

31.25

.5678

Duration injecting (years)

4

4

5.25

.0612

No. of barriers (median)

5

5.5

5

.7227

Most frequently reported barrier

Fear of arrest

Fear of arrest

Fear of arrest

Barriers to new needle use

*Test for the difference between the Health Department and the LIGHT Program

Barriers to using new needles
Number of barriers reported

The median number of barriers to using new needles
among all participants was 5 (range 0–19). PWID who
reported > 8 barriers were significantly older than those
reporting < 4 barriers (41.87 years vs. 35.68 years, respectively; P = .02). PWID who had been injecting for
at least 8 years were significantly more likely to report
> 8 barriers to new needle use compared to those

injecting for < 3 years (41.67% versus 12.50%, respectively;
P = .048). There were no other significant differences (all
P > .05) in the number of barriers reported between sites,
demographic categories, or by frequency of injection.
Barriers reported by more than half of respondents

Among all 20 barriers, three items were endorsed by at
least 50% of respondents (see Table 2). Two of these
barriers related to obtaining new needles at pharmacies
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Table 2 Reported barriers to using new needles by people who inject drugs (N = 100)
Agree

Disagree/neutral

%

%

1. It takes too long to get a new needle every time I inject.

15

85

2. It is inconvenient to get a new needle every time I inject.

24.74

75.26

3. I often do not want to take the time to get a new needle because my cravings or urges to use drugs are too strong.

18.37

81.63

4. I often do not take the time to get a new needle if I am drug sick or in withdrawal.

24.45

75.55

5. I do not take the time to get a new needle before injecting because I can only think about getting high.

23.23

76.77

6. I do not take the time to get a new needle before injecting if I am already high or drunk.

19.39

80.61

7. The places where I inject usually do not have access to new needles.

29.29

70.71

8. If I am in a shooting gallery (a place where people inject drugs, “dope den,” “joy popping,” etc.), I often do not
use a new needle.

21.74

78.26

9. I often do not carry new needles with me when I am out.

30.93

69.07

10. There is not a needle exchange close by for me to get needles.

16.67

83.33

11. Pharmacies sometimes give me hassle when I try to buy needles.

63.33

36.37

12. After I inject, I do not prepare in advance by getting new needles ready for my next injection.

39.80

60.20

13. It’s too expensive to buy new needles from the pharmacy for every time I inject.

55.91

44.09

14. Feeling sad or depressed would get in the way of my using a new needle every time I inject.

20.21

79.79

15. It is embarrassing to buy needles at the pharmacy.

47.92

52.08

16. I worry that someone (friends, family, etc.) may see me buying needles at the pharmacy.

49.47

50.53

17. My peers/friends would look at me funny if I used a new needle every time I inject.

17.53

82.47

18. Having to worry about using a new needle interrupts the ritual of using.

16.84

83.16

19. I am unlikely to use a new needle if a friend lets me borrow his or her used needle.

19.59

80.41

20. I could get in trouble from the police if I carry needles around with me.

72.00

28.00

(items 11 and 13), and one reflected fear of arrest (item
20). Fear of arrest was the most frequently cited barrier
overall with 45% of respondents strongly agreeing and
an additional 27% agreeing that it was a barrier to using
new needles. Agreement with these three items did not
differ significantly (all P > .05) by age, gender, race, ethnicity, education, employment status, housing status, HCV
status, or injection history. Therefore, we did not construct additional multivariate models potentially controlling for confounders.

Discussion
We conducted the first study to empirically assess barriers
to using new needles by PWID living in the Appalachian
region of the US that is currently in the midst of an opioid
and HCV epidemic. As hypothesized, similar to previous
studies, fear of arrest by law enforcement officials was the
most frequently reported barrier to using new needles in
our population. However, we did not find being in withdrawal to be a significant barrier to new needle use as we
expected. Rather, difficulty obtaining new needles from
pharmacies was the second most frequently cited barrier.
These findings may have implications for the efficacy of
NEPs for the prevention of HCV and other infectious
diseases among PWID.

The overall number of barriers reported was slightly larger in the Denver sample compared to our study (average
of 7.19 (SD, 3.62) barriers reported versus 6.02 (SD, 4.61),
respectively). However, similar to our findings, only a
small proportion of barriers was endorsed by at least 50%
of respondents. More specifically, only 5 of 20 barriers
were endorsed by more than 50% of respondents in Denver, and only 3 of 20 barriers were endorsed by more than
50% in our rural setting, although an additional 2 barriers
related to difficulties purchasing new syringes at a
pharmacy (items 15 and 16) were endorsed by almost
half of our sample.
Notably, and congruent with our findings, fear of arrest
for carrying new needles was the most frequently cited
barrier in Denver (98% of injectors, 45 of 48). This finding
is also congruent with several other studies conducted in
the following large, urban areas: Baltimore, MD [19, 41],
Oakland, CA, Richmond, CA [16], Los Angeles, CA
[14, 15], and San Francisco, CA [42], in the US and
Moscow, Volgograd, and Barnaul in Russia [23]. To our
knowledge, this work is the first to quantitatively assess
this phenomenon in rural Appalachia and is congruent
with a recent qualitative case study of rural Appalachian
NEPs by Davis et al. [43]. This case study observed a legal
conundrum created by paraphernalia laws that manifested
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in PWID being cited for new needle possessions. West
Virginia state law does not regulate the retail sale of
syringes [44]. However, some West Virginia cities are
passing ordinances that criminalize needle possession
in the absence of a prescription [45]. This development
may limit the ability of PWID to have a new needle
available for every injection, which may increase the
risk of HCV seroconversion and undermine the infectious disease prevention goals of NEPs.
Even in locations that do not prohibit syringe possession, the success of NEPs is directly contingent on close
cooperation between law enforcement and public health
officials. In particular, Beletsky [46] noted a discrepancy
between the “law on the books” (i.e., legality of syringe
possession and exchange) and the “law on the streets” (i.e.,
discretionary behavior of law enforcement in the form of
arrests and citations for needle possession) [46]. Therefore, a better understanding of law enforcement attitudes
underlying variable enforcement behaviors is indicated.
Elucidation of these attitudes can form the basis of
tailored interventions to promote law enforcement
acceptance of NEPs at a local or regional level to improve
success and acceptability [47].
Interestingly, the difficulties related to purchasing
syringes at pharmacies observed in our study were not
reported in the urban, Denver sample, although the
legality of syringe sales was similar to our own setting
(i.e., no explicit law prohibiting nonprescription sales to
PWID) [48, 49]. Therefore, these sales are left to the
discretion of pharmacists who often have to weigh the public health goal of preventing infectious disease with concerns over endorsement of drug use, which may contribute
to practice variability (Garofoli M, e-mail communication,
7 Nov 2017). Such variability has been documented in the
US with syringe purchase refusal rates between 23 and 79%
observed in states where nonprescription sale of syringes by
pharmacies is legal [50–52]. Concerns over endorsement of
drug use and stigmatization of drug users were among
the factors associated with these refusals [50]. As a
result of these findings, there has been a call to pass legislation that explicitly mandates pharmacy sales of nonprescription syringes as opposed to current discretionary
practices [50, 53]. Education of pharmacists to promote
awareness of existing state laws that allow nonprescription
sales of new needles and the efficacy of new needle use in
preventing infectious diseases has been advanced [50, 53].
Pharmacy policies that explicitly promote nonprescription
syringe sales have been encouraged [54]. Fuller et al. [55]
implemented a multilevel community-based intervention
that was successful in reducing negative opinions of pharmacy syringe sales to PWID among both community
members and pharmacists. This study also observed
increased purchase of syringes by PWID and a significant
decrease in syringe reuse. Given the recent closing of a
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West Virginia NEP over public concerns regarding discarded needles [56], and the fact that the 4 of the top 5
barriers were related to pharmacy sales (i.e., Q11, Q13,
Q15, Q16), pharmacy syringe distribution to PWID may
be a viable alternative source of new needles and is a topic
worthy of additional inquiry and research.
Finally, we did not find being in withdrawal to be a
barrier to using new needles in our rural sample as was
observed in Denver. Whereas only one quarter of our respondents cited being in withdrawal as a barrier to using
new needles in our setting, 65% either agreed or strongly
agreed that this was a barrier in Denver, Colorado. Keyes
et al. [57] has hypothesized a greater availability of
opioids in rural areas due to tight social networks and kinship that serve as a source of prescription opioids. This
hypothesis may partially explain the lack of association
with withdrawal in our setting. However, it is unclear if
this tight social network also increases the availability of
nonprescription, illicit opioids (i.e., heroin) that were the
most reported drugs of choice in the current study. Therefore, potential explanations for this discrepancy are
unclear and warrant further investigation. It is also unclear
whether these tight social networks increase access to new
needles in the form of secondary exchange from NEP
attendees. Des Jarlais et al. [29] reported that an estimated
30% of syringes obtained from rural NEPs are distributed
via secondary exchange/peer delivery services. However,
these data were reported by NEP directors and not the
NEP attendees themselves.
Our findings are subject to some limitations. The
results may be subject to reporting bias, specifically in the
form of social desirability bias. However, we employed an
anonymous survey design to minimize this source of bias.
Additionally, given the hard-to-reach PWID population,
we were not able to employ a random sampling scheme,
which may have biased our results. Such bias could affect
the generalizability of our findings both to other injectors
attending the two NEP sites in our study and also to
PWID attending other NEPs located within West Virginia
(9 additional NEPs have opened in West Virginia [58],
since the first two that were selected for this study). Our
results may also underestimate barriers to new needle use
due to the fact that we only recruited PWID attending
needle exchanges where some needle access is provided.
Although we found no significant differences between
participants at both NEPs on selected characteristics, the
variable program characteristics of the NEPs included in
our study (i.e., one operated by a health department and
one operated by a free healthcare clinic) may have
contributed to differential participation patterns by PWID
that may limit generalizability of our findings. Furthermore, these results may not be applicable to PWID in
other locales outside of the rural, Appalachian environment or even to other PWID in West Virginia. Finally,
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our primary findings are descriptive and could be subject
to confounding effects.
These limitations notwithstanding, we were able to
provide heretofore-unknown information on new needle
use barriers experienced by PWID at the epicenter of
the current national HCV epidemic. Future studies
should measure the impact of reported barriers on risky
injection behavior and seek to confirm these results in
other locales. Future studies should also specifically
examine the impact of paraphernalia laws and policing
behaviors on the efficacy of the needle exchange model
in rural Appalachian settings.

Ethics approval and consent to participate
The West Virginia University Institutional Review Board approved the
protocol (IRB#1707657397) and waived the requirement for written
documentation of consent.

Conclusions
Fear of arrest for possessing new needles and difficulties
with pharmacy purchase of new needles were the most
commonly cited barriers to using new needles among
our population of injection drug users attending two
NEPs in rural West Virginia. Future studies should confirm these results in other rural settings and explore the
design and implementation of individual and structural
interventions with law enforcement officials and pharmacists that promote access to sterile syringes and support the overall efficacy of the needle exchange model.
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